Article Says "AMRN Average PT is $17.65 / AMRN Very Undervalued ". LINKED
May 17, 2013 By' Pearson-Lardman Article Where Is Amarin Really?
Not to mention the Big Name and More Reputable Institutions like Jefferies, JP Morgan, Leerink Swan, Canaccord and Citi have Price Targets from $13-$39, with an average PT of $17.65 however, these go overlooked and pushed to the side.
In conclusion you can make all the speculation you want around NCE, but with the Patent Portfolio that AMRN has built up and the FACT that Vascepa will be the 1st ever drug to enter the ANCHOR Market, NCE clearly does not justify why AMRN should be trading at the $7-$8 range. In my opinion AMRN is very undervalued at this level and hopefully the continued week to week and month to month script growth aswell as the upcoming Combo-Statin Data will help get AMRN stock to a level of true valuation before the drug Launches in the ANCHOR Market and/or Partners up with a Big Pharma.